Low-molecular-weight heparin during pregnancy

Thrombosis Research

Volumn 101, Issue 1, 2001, Pages 175-186

  Bazzan, M ^a   Donvito, V ^b  

^a Ospedale Evangelico Valdese   (Italy)

^b Dipartimento di Medicina Interna   (Italy)

Author keywords

Heparin; Low molecular weight heparin; Pregnancy; Venous thromboembolism

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULANT THERAPY; BLOOD PLACENTA BARRIER; BONE DYSPLASIA; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FEMALE; HUMAN; PREGNANCY; PRIORITY JOURNAL; PUERPERIUM; REVIEW; SPONTANEOUS ABORTION; THROMBOEMBOLISM; THROMBOPHILIA; VEIN DILATATION; VENOUS STASIS;

FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; RISK FACTORS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 0035126087     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(00)00403-5     Document Type: Article

References (55)

1. Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis
2. Comparison of subcutaneous low molecular weight heparin with intravenous standard heparin in proximal deep vein thrombosis
3. Low molecular weight heparins
4. Low molecular weight heparin use during pregnancy: Issues of safety and praticality
5. Anticoagulation with low-molecular weight heparin during pregnancy
6. Venous thrombotic complications of pregnancy
7. Maternal morbidity in the United States 1979-1986
8. Maternal mortality in Sweden
9. Thromboembolic disease associated with pregnancy: An 11 year review
10. Controversies in thromboembolic disease during pregnancy: A critical review
11. Haemostatic variables in normal pregnancy
12. Thrombosis in pregnancy: Maternal and fetal issues
13. Long term outcome of patients with venous thromboembolism during pregnancy
14. Low risk of recurrent thromboembolism in pregnancy
15. Elevation of FVIII:C in venous thromboembolism is persistent and independent of the acute phase response
16. High levels of coagulation factor XI as a risk factor for venous thrombosis
17. Heritable coagulopathies in pregnancy
18. Increased frequency of genetic thrombophilia in women with complications of pregnancy
19. The role of inherited thrombophilia in venous thromboembolism associated with pregnancy
20. Effect of heparin for preventing fetal loss due to placental insufficiency in women with inherited thrombophilia
21. Safety of low-molecular-weight heparin in pregnancy: A systematic review
22. Changes in pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy
23. Low molecular weight heparins and their use in obstetric and gynecology
24. Maternal and fetal sequelae of anticoagulation during pregnancy
25. Chondrodysplasia punctata: Is maternal warfarin a factor?
26. Risks to the fetus of anticoagulant therapy during pregnancy
27. A low molecular weight heparin alters the fetal coagulation system in the pregnant sheep
28. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy. Study by direct fetal blood sampling on ultrasound
29. Low molecular weight heparin as thromboprophilaxis in pregnancy
30. May mothers given warfarin breast feed their infants?
31. Is warfarin sodium contraindicated in the lactating mother?
32. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractioned heparin
33. Osteoporotic fractures and recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophilaxis with heparin
34. Comparison of subcutaneous unfractionated heparin with a low molecular heparin (Frogman) in patients with venous thromboembolism and contraindications to heparin
35. Use of antithrombotic agents during pregnancy
36. Outcome of pregnancy in women with valve prostheses
37. Failure of adjusted dose of subcutaneous heparin to prevent thromboembolic phenomena in pregnant patients with mechanical cardiac valve prostheses
38. Low molecular weight heparin for thromboprophylaxis during pregnancy in 2 patients with mechanical mitral valve replacement
39. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop
40. Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone
41. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)
42. Low dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy-induced hypertension
43. Low dose aspirin to prevent pre-eclampsia in women at high risk
44. Prevention of preeclampsia by early antiplatelet therapy
45. Effect of low dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy induced hypertension
46. Thrombosis in pregnancy
47. Thrombophilias and adverse outcomes of pregnancy. What should a clinician do?
48. Does ovarian stimulation for in vitro fertilization induce a hypercoagulable state?
49. Studies of the coagulation and fibrinolytic systems in ovarian hyperstimulation after administration of human gonadotropins
50. Subclavian vein thrombosis: A late complication of ovarian hyperstimulation syndrome
51. Risk of thromboembolism in relation to an in-vitro fertilisation programme: Three case reports
52. Internal jugular vein thrombosis: A late complication of ovarian hyperstimulation syndrome despite mini-dose heparin prophylaxis
53. Venous thromboembolism after cesarean section: A prospective cohort study